These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33375314)

  • 1. Predefined Diets in Patients with Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Comeche JM; Gutierrez-Hervás A; Tuells J; Altavilla C; Caballero P
    Nutrients; 2020 Dec; 13(1):. PubMed ID: 33375314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteral Nutrition in Patients with Inflammatory Bowel Disease. Systematic Review, Meta-Analysis, and Meta-Regression.
    Comeche JM; Caballero P; Gutierrez-Hervas A; García-Sanjuan S; Comino I; Altavilla C; Tuells J
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral Nutrition in Patients with Inflammatory Bowel Disease Systematic Review, Meta-Analysis and Meta-Regression.
    Comeche JM; Comino I; Altavilla C; Tuells J; Gutierrez-Hervas A; Caballero P
    Nutrients; 2019 Nov; 11(12):. PubMed ID: 31766687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Mediterranean Diet's Adherence in children with Inflammatory Bowel Diseases.
    Strisciuglio C; Cenni S; Serra MR; Dolce P; Martinelli M; Staiano A; Miele E
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33092159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
    Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
    Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
    Menees SB; Powell C; Kurlander J; Goel A; Chey WD
    Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease.
    Konijeti GG; Kim N; Lewis JD; Groven S; Chandrasekaran A; Grandhe S; Diamant C; Singh E; Oliveira G; Wang X; Molparia B; Torkamani A
    Inflamm Bowel Dis; 2017 Nov; 23(11):2054-2060. PubMed ID: 28858071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
    Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
    Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.